BHEKISISA: Anti-HIV jab due in six weeks but funding cuts

South Africa's ambitious rollout of lenacapavir (LEN), a groundbreaking long-acting HIV prevention injection administered every six months, faces severe operational headwinds as the Trump administration implements targeted funding reductions to the country's health sector. New research from Bhekisisa Centre for Health Journalism, based on in-depth interviews with frontline healthcare workers, reveals that anticipated US aid cuts will directly constrain the scaling of this prevention tool across Cape Town, Johannesburg, and beyond—jeopardizing access for vulnerable populations who need it most.

The timing is critical. Lenacapavir, approved by South Africa's health regulator, represents a watershed moment in HIV prevention science: a two-dose initiation followed by quarterly injections provides 99% efficacy in clinical trials. Yet this innovation sits at the intersection of epidemiology and geopolitics, where funding uncertainty now threatens implementation.

## How do US aid cuts directly impact HIV prevention rollout?

The United States, through PEPFAR (President's Emergency Plan for AIDS Relief), has historically anchored South Africa's HIV response with approximately $285 million annually. PEPFAR funds don't just pay for drugs—they finance the entire ecosystem: nurse training, clinic infrastructure, supply chain logistics, and community outreach. When PEPFAR allocations shrink, that ecosystem contracts. Healthcare workers interviewed reported delays in procurement authorizations, hiring freezes for community health workers, and uncertainty around inventory forecasting. For lenacapavir, which requires specialized training and cold-chain management, these gaps are existential. A clinic without trained staff or reliable supply lines cannot dispense a drug effectively, regardless of efficacy.

The research underscores a stark reality: South Africa's healthcare system, while the continent's most advanced, remains externally dependent. Local pharmaceutical manufacturers exist, but domestic budget capacity hasn't closed the funding gap PEPFAR historically filled. With the Trump administration signaling deeper cuts to international health aid, the risk is not that lenacapavir won't work—it's that it won't reach those who need it.

## Why does lenacapavir matter for young women and key populations?

South Africa recorded 210,000 new HIV infections in 2024, concentrated among young women (15-24) and key populations including sex workers, gay and bisexual men, and transgender individuals. Lenacapavir's six-month dosing schedule overcomes a critical barrier: adherence to daily PrEP (pre-exposure prophylaxis) pills. For sex workers managing irregular income, housing instability, and stigma, a quarterly injection is operationally superior. The Bhekisisa interviews reveal that healthcare workers expected LEN to improve uptake precisely *because* it reduced the burden of daily clinic visits. Funding cuts now threaten to deny this population a tool purpose-built for their circumstances.

## What is the broader investment signal?

The lenacapavir rollout cuts expose a deeper vulnerability in African health innovation: dependence on donor cycles rather than domestic or blended finance mechanisms. For investors and policymakers, this signals both risk and opportunity. South African healthcare stocks may face near-term headwinds, but the long-term case for local manufacturing and regional self-sufficiency strengthens—positioning companies that can capture this transition as infrastructure beneficiaries.